The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Biologic Treatment of Severe Asthma

중증천식의 생물학적 제제 치료

  • Kim, Min-Hye (Department of Internal Medicine, Mokdong Hospital, Ewha Womans University School of Medicine)
  • 김민혜 (이화여자대학교 의과대학 이대목동병원 내과)
  • Published : 2018.04.01
⟨ Previous Next ⟩

Abstract

Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.

Keywords

References

  1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109(5 Suppl):S482-S489. https://doi.org/10.1067/mai.2002.122716
  2. Cho SH, Park HW, Rosenberg DM. The current status of asthma in Korea. J Korean Med Sci 2006;21:181-187. https://doi.org/10.3346/jkms.2006.21.2.181
  3. Kim SH, Kim TW, Kwon JW, et al. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals. J Asthma 2012;49:303-309. https://doi.org/10.3109/02770903.2011.641046
  4. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-373. https://doi.org/10.1183/09031936.00202013
  5. Katial RK, Bensch GW, Busse WW, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5(2S):S1-S14. https://doi.org/10.1016/j.jaip.2016.11.029
  6. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention [Internet]. Global Initiative for Asthma (GINA), c2017 [cited 2017 Feb 28]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-forasthma-management-and-prevention/.
  7. Newby C, Heaney LG, Menzies-Gow A, et al. Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. PloS one 2014;9:e102987. https://doi.org/10.1371/journal.pone.0102987
  8. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008. https://doi.org/10.1164/ajrccm.160.3.9812110
  9. Schleich F, Brusselle G, Louis R, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med 2014;108:1723-1732. https://doi.org/10.1016/j.rmed.2014.10.007
  10. Diver S, Russell RJ, Brightling CE. New and emerging drug treatments for severe asthma. Clin Exp Allergy 2018;48:241-252. https://doi.org/10.1111/cea.13086
  11. Chang HS, Lee TH, Jun JA, et al. Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations. Expert Rev Respir Med 2017;11:29-40. https://doi.org/10.1080/17476348.2017.1268919
  12. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-2695. https://doi.org/10.1056/NEJMct055184
  13. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190. https://doi.org/10.1067/mai.2001.117880
  14. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261. https://doi.org/10.1183/09031936.01.00092101
  15. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-582. https://doi.org/10.7326/0003-4819-154-9-201105030-00002
  16. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139: 28-35. https://doi.org/10.1378/chest.10-1194
  17. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;(1):CD003559.
  18. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483-1492. https://doi.org/10.1016/j.rmed.2007.01.011
  19. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009;64:1780-1787. https://doi.org/10.1111/j.1398-9995.2009.02119.x
  20. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-811. https://doi.org/10.1164/rccm.201208-1414OC
  21. Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525-536.e1. https://doi.org/10.1016/j.jaip.2014.03.010
  22. Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012;129:983-989.e6. https://doi.org/10.1016/j.jaci.2012.01.033
  23. Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014;134:560-567.e4. https://doi.org/10.1016/j.jaci.2014.02.007
  24. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-984. https://doi.org/10.1056/NEJMoa0808991
  25. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-659. https://doi.org/10.1016/S0140-6736(12)60988-X
  26. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-1207. https://doi.org/10.1056/NEJMoa1403290
  27. Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol 2017; 139:1167-1175.e2. https://doi.org/10.1016/j.jaci.2016.08.008
  28. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-993. https://doi.org/10.1056/NEJMoa0805435
  29. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-1197. https://doi.org/10.1056/NEJMoa1403291
  30. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 2017;5:390-400. https://doi.org/10.1016/S2213-2600(17)30125-X
  31. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 2014;133:921-923. https://doi.org/10.1016/j.jaci.2013.11.026
  32. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355-366. https://doi.org/10.1016/S2213-2600(15)00042-9
  33. Brusselle G, Canvin J, Weiss S, et al. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. ERJ Open Res 2017;3:00004-2017.
  34. Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med 2018;197:38-46. https://doi.org/10.1164/rccm.201707-1323OC
  35. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-1244.e2. https://doi.org/10.1016/j.jaci.2010.04.005
  36. Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:879-890. https://doi.org/10.1016/S2213-2600(14)70201-2
  37. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;388:2128-2141. https://doi.org/10.1016/S0140-6736(16)31322-8
  38. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ${\beta}2$-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016;388:2115-2127. https://doi.org/10.1016/S0140-6736(16)31324-1
  39. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 2018;6:51-64. https://doi.org/10.1016/S2213-2600(17)30344-2
  40. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 2017;376:2448-2458. https://doi.org/10.1056/NEJMoa1703501
  41. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-2466. https://doi.org/10.1056/NEJMoa1304048
  42. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ${\beta}$-2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016;388:31-44. https://doi.org/10.1016/S0140-6736(16)30307-5
  43. Dunn RM, Wechsler ME. Anti-interleukin therapy in asthma. Clin Pharmacol Ther 2015;97:55-65. https://doi.org/10.1002/cpt.11
  44. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315:469-479. https://doi.org/10.1001/jama.2015.19330
  45. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017;389:2287-2303. https://doi.org/10.1016/S0140-6736(17)31191-1
  46. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016;4:781-796. https://doi.org/10.1016/S2213-2600(16)30265-X
  47. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015;3:692-701. https://doi.org/10.1016/S2213-2600(15)00197-6
  48. Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin $D_2$ pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol 2013;131:1504-1512. https://doi.org/10.1016/j.jaci.2013.01.035
  49. Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016;4:699-707. https://doi.org/10.1016/S2213-2600(16)30179-5
  50. Shikotra A, Choy DF, Ohri CM, et al. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012;129:104-111.e1-e9. https://doi.org/10.1016/j.jaci.2011.08.031
  51. Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102-2110. https://doi.org/10.1056/NEJMoa1402895
  52. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017;377:936-946. https://doi.org/10.1056/NEJMoa1704064
  53. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-558. https://doi.org/10.1164/rccm.200809-1512OC
  54. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 2008;63:584-591. https://doi.org/10.1136/thx.2007.086314
  55. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011;37:1352-1359. https://doi.org/10.1183/09031936.00063510
  56. O'Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebocontrolled trial. Lancet Respir Med 2016;4:797-806. https://doi.org/10.1016/S2213-2600(16)30227-2
  57. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294-1302. https://doi.org/10.1164/rccm.201212-2318OC

Cited by

  1. 천식환자 허실변증별 혈액 싸이토카인 및 임상적 특성에 관한 단면적 연구 vol.41, pp.4, 2020, https://doi.org/10.22246/jikm.2020.41.4.583